Compare NextEra Energy, Inc. (NEE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? NextEra Energy, Inc. trades at $77.33 (market cap $160.75B), while State Street SPDR S&P Biotech ETF trades at $149.82 (market cap $10.08B). The key difference: NextEra Energy, Inc. is far larger — about 15.9× State Street SPDR S&P Biotech ETF's market cap, and NextEra Energy, Inc. pays a 3.23% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold NextEra Energy, Inc. for 83 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| NEE | XBI | |
|---|---|---|
Market Cap | $160.75B | $10.08B |
Volume | 10,598,021 | 9,534,635 |
Sector | Utilities | Broad Market / Factor |
52-Week High | $97.88 | $169.55 |
52-Week Low | $75.49 | $104.99 |
Typical Hold Time | 83 Days | 37 Days |
Enterprise Value | $268.08B | — |
Dividend Yield | 3.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $77.06, down 1.05% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a 32.4% net income margin and consistent earnings beats in recent quarters, though it missed in Q4 2025. Recent news highlights growth initiatives, including a $22.3 billion energy infrastructure project in Texas announced on September 30, 2026.
The outlook remains positive with a consensus price target of $96.00, implying 25% upside, supported by robust cash flow and profitability. Risks include rising debt levels, with debt-to-asset ratio increasing to 47.6% in 2025, and sensitivity to interest rate changes. Analyst sentiment is bullish with 66.66% buy ratings, but technical weakness near 52-week lows warrants caution.
XBI trades at $150.23, down 0.44% on the day, with bearish technical signals dominating. The ETF faces resistance near $152-154 while finding support at $147-149 levels. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech sector optimism from M&A activity and cancer vaccine breakthroughs. The fund's 0.35% expense ratio compares unfavorably to broader healthcare ETFs but offers targeted biotech exposure.
Outlook remains mixed with technical weakness offset by sector catalysts. The biotech focus provides growth potential but carries higher volatility than diversified healthcare alternatives. Key risks include sector-specific regulatory pressures and the fund's expense structure, while opportunities exist from ongoing pharmaceutical innovation and capital market improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
